In this Friday’s PCT Grand Rounds, Jeffrey Carson of Rutgers Biomedical and Health Sciences will present “Clinical Implications of the MINT Trial: p=0.07.”
The Grand Rounds session will be held on Friday, February 16, 2024, at 1:00 pm eastern.
Carson is provost-New Brunswick for Rutgers Biomedical and Health Sciences and the Distinguished Professor of Medicine and Richard C. Reynolds, MD, Chair in General Internal Medicine at Rutgers Robert Wood Johnson Medical School.
Carson will discuss the clinical implications of the Myocardial Ischemia and Transfusion (MINT) trial, a pragmatic clinical trial that did not show a significant difference between the study arms in the primary outcome yet consistently favored one intervention strategy in the point estimates for the primary and secondary outcomes.
The goal of the MINT trial was to determine whether the risk of recurrent myocardial infarction or death at 30 days differed between a restrictive transfusion strategy and a liberal transfusion strategy among patients with an acute myocardial infarction and anemia. The pragmatic trial’s broad inclusion criteria resulted in a study population with a variety of diagnoses and coexisting illnesses that was generally representative of patients in clinical practice. The trial’s transfusion protocols approximated clinical practice in a variety of healthcare settings.